{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:50:12Z","timestamp":1761630612001},"reference-count":197,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2012,4,3]],"date-time":"2012-04-03T00:00:00Z","timestamp":1333411200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s10620-012-2151-2","type":"journal-article","created":{"date-parts":[[2012,4,2]],"date-time":"2012-04-02T04:43:34Z","timestamp":1333341814000},"page":"1996-2010","source":"Crossref","is-referenced-by-count":36,"title":["Advances in the Current Treatment of Autoimmune Hepatitis"],"prefix":"10.1007","volume":"57","author":[{"given":"Albert J.","family":"Czaja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,4,3]]},"reference":[{"key":"2151_CR1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/oxfordjournals.qjmed.a067264","volume":"40","author":"GC Cook","year":"1971","unstructured":"Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med. 1971;40:159\u2013185.","journal-title":"Q J Med"},{"key":"2151_CR2","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0016-5085(19)33223-8","volume":"63","author":"RD Soloway","year":"1972","unstructured":"Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology. 1972;63:820\u2013833.","journal-title":"Gastroenterology"},{"key":"2151_CR3","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(73)92125-9","volume":"1","author":"IM Murray-Lyon","year":"1973","unstructured":"Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet. 1973;1:735\u2013737.","journal-title":"Lancet"},{"key":"2151_CR4","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2004.01.009","volume":"40","author":"AJ Czaja","year":"2004","unstructured":"Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol. 2004;40:646\u2013652.","journal-title":"J Hepatol"},{"key":"2151_CR5","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s10620-005-2472-5","volume":"50","author":"M Mohamadnejad","year":"2005","unstructured":"Mohamadnejad M, Malekzadeh R, Nasseri-Moghaddam S, et al. Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis. Dig Dis Sci. 2005;50:547\u2013551.","journal-title":"Dig Dis Sci"},{"key":"2151_CR6","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1053\/gast.1996.v110.pm8608895","volume":"110","author":"SK Roberts","year":"1996","unstructured":"Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology. 1996;110:848\u2013857.","journal-title":"Gastroenterology"},{"key":"2151_CR7","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1365-2036.2006.03104.x","volume":"24","author":"A Floreani","year":"2006","unstructured":"Floreani A, Niro G. Rosa Rizzotto E, et al. Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment Pharmacol Ther. 2006;24:1051\u20131057.","journal-title":"Aliment Pharmacol Ther"},{"key":"2151_CR8","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/j.1440-1746.2008.05365.x","volume":"23","author":"S Seo","year":"2008","unstructured":"Seo S, Toutounjian R, Conrad A, Blatt L, Tong MJ. Favorable outcomes of autoimmune hepatitis in a community clinic setting. J Gastroenterol Hepatol. 2008;23:1410\u20131414.","journal-title":"J Gastroenterol Hepatol"},{"key":"2151_CR9","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/hep.23584","volume":"51","author":"MP Manns","year":"2010","unstructured":"Manns MP, Czaja AJ, Gorham JD, et al. Practice guidelines of the American association for the study of liver diseases. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193\u20132213.","journal-title":"Hepatology"},{"key":"2151_CR10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/hep.20539","volume":"41","author":"AJ Czaja","year":"2005","unstructured":"Czaja AJ, Bianchi FB, Carpenter HA, et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology. 2005;41:207\u2013215.","journal-title":"Hepatology"},{"key":"2151_CR11","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/hep.21787","volume":"46","author":"AJ Montano-Loza","year":"2007","unstructured":"Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology. 2007;46:1138\u20131145.","journal-title":"Hepatology"},{"key":"2151_CR12","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/hep.1840040409","volume":"4","author":"AJ Czaja","year":"1984","unstructured":"Czaja AJ, Davis GL, Ludwig J, Taswell HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology. 1984;4:622\u2013627.","journal-title":"Hepatology"},{"key":"2151_CR13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1517\/14740338.7.3.319","volume":"7","author":"AJ Czaja","year":"2008","unstructured":"Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf. 2008;7:319\u2013333.","journal-title":"Expert Opin Drug Saf"},{"key":"2151_CR14","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/0016-5085(80)90866-5","volume":"78","author":"AJ Czaja","year":"1980","unstructured":"Czaja AJ, Ammon HV, Summerskill WH. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology. 1980;78:518\u2013523.","journal-title":"Gastroenterology"},{"key":"2151_CR15","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/hep.1840030510","volume":"3","author":"JE Hegarty","year":"1983","unstructured":"Hegarty JE, Nouri Aria KT, Portmann B, Eddleston AL, Williams R. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology. 1983;3:685\u2013689.","journal-title":"Hepatology"},{"key":"2151_CR16","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1053\/jhep.2002.32485","volume":"35","author":"AJ Czaja","year":"2002","unstructured":"Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology. 2002;35:890\u2013897.","journal-title":"Hepatology"},{"key":"2151_CR17","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1586\/egh.09.15","volume":"3","author":"AJ Czaja","year":"2009","unstructured":"Czaja AJ. Current and future treatments of autoimmune hepatitis. Expert Rev Gastroenterol Hepatol. 2009;3:269\u2013291.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2151_CR18","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1007\/s10620-009-1122-8","volume":"55","author":"AJ Czaja","year":"2010","unstructured":"Czaja AJ. Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis. Dig Dis Sci. 2010;55:2712\u20132726.","journal-title":"Dig Dis Sci"},{"key":"2151_CR19","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.2174\/138161211798157568","volume":"17","author":"AJ Czaja","year":"2011","unstructured":"Czaja AJ. Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis. Curr Pharm Design. 2011;17:3120\u20133140.","journal-title":"Curr Pharm Design"},{"key":"2151_CR20","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","volume":"31","author":"F Alvarez","year":"1999","unstructured":"Alvarez F, Berg PA, Bianchi FB, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929\u2013938.","journal-title":"J Hepatol"},{"key":"2151_CR21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/j.gastro.2010.04.053","volume":"139","author":"AJ Czaja","year":"2010","unstructured":"Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis and management of autoimmune hepatitis. Gastroenterology. 2010;139:58\u201372.","journal-title":"Gastroenterology"},{"key":"2151_CR22","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/0016-5085(87)90454-9","volume":"93","author":"JS Hyams","year":"1987","unstructured":"Hyams JS, Ballow M, Leichtner AM. Cyclosporine treatment of autoimmune chronic active hepatitis. Gastroenterology. 1987;93:890\u2013893.","journal-title":"Gastroenterology"},{"key":"2151_CR23","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/00004836-199312000-00012","volume":"17","author":"JL Person","year":"1993","unstructured":"Person JL, McHutchison JG, Fong TL, Redeker AG. A case of cyclosporine-sensitive, steroid-resistant, autoimmune chronic active hepatitis. J Clin Gastroenterol. 1993;17:317\u2013320.","journal-title":"J Clin Gastroenterol"},{"key":"2151_CR24","first-page":"771","volume":"90","author":"DH Thiel Van","year":"1995","unstructured":"Van Thiel DH, Wright H, Carroll P, et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol. 1995;90:771\u2013776.","journal-title":"Am J Gastroenterol"},{"key":"2151_CR25","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1136\/gut.36.3.459","volume":"36","author":"LD Jackson","year":"1995","unstructured":"Jackson LD, Song E. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut. 1995;36:459\u2013461.","journal-title":"Gut"},{"key":"2151_CR26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0022-3476(99)70339-2","volume":"135","author":"D Debray","year":"1999","unstructured":"Debray D, Maggiore G, Girardet JP, Mallet E, Bernard O. Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. J Pediatr. 1999;135:111\u2013114.","journal-title":"J Pediatr"},{"key":"2151_CR27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1572-0241.1999.00807.x","volume":"94","author":"NF Fernandes","year":"1999","unstructured":"Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol. 1999;94:241\u2013248.","journal-title":"Am J Gastroenterol"},{"key":"2151_CR28","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1023\/A:1010683817344","volume":"46","author":"R Malekzadeh","year":"2001","unstructured":"Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, et al. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci. 2001;46:1321\u20131327.","journal-title":"Dig Dis Sci"},{"key":"2151_CR29","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1053\/jlts.2001.24638","volume":"7","author":"M Hurtova","year":"2001","unstructured":"Hurtova M, Duclos-Vallee JC, Johanet C, et al. Successful tacrolimus therapy for a severe recurrence of type 1 autoimmune hepatitis in a liver graft recipient. Liver Transpl. 2001;7:556\u2013558.","journal-title":"Liver Transpl"},{"key":"2151_CR30","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/01.mcg.0000139050.67178.be","volume":"38","author":"BA Aqel","year":"2004","unstructured":"Aqel BA, Machicao V, Rosser B, et al. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol. 2004;38:805\u2013809.","journal-title":"J Clin Gastroenterol"},{"key":"2151_CR31","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.3748\/wjg.v13.i26.3610","volume":"13","author":"FS Larsen","year":"2007","unstructured":"Larsen FS, Vainer B, Eefsen M, Bjerring PN, Adel Hansen B. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol. 2007;13:3232\u20133236.","journal-title":"World J Gastroenterol"},{"key":"2151_CR32","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2036.2011.04749.x","volume":"34","author":"MM Tannous","year":"2011","unstructured":"Tannous MM, Cheng J, Muniyappa K, et al. Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience. Aliment Pharmacol Ther. 2011;34:405\u2013407.","journal-title":"Aliment Pharmacol Ther"},{"key":"2151_CR33","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2036.1994.tb00334.x","volume":"8","author":"A Danielsson","year":"1994","unstructured":"Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther. 1994;8:585\u2013590.","journal-title":"Aliment Pharmacol Ther"},{"key":"2151_CR34","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1478-3231.2005.01122.x","volume":"25","author":"J Wiegand","year":"2005","unstructured":"Wiegand J, Schuler A, Kanzler S, et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int. 2005;25:927\u2013934.","journal-title":"Liver Int"},{"key":"2151_CR35","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3748\/wjg.v12.i9.1362","volume":"12","author":"A Csepregi","year":"2006","unstructured":"Csepregi A, Rocken C, Treiber G, Malfertheiner P. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol. 2006;12:1362\u20131366.","journal-title":"World J Gastroenterol"},{"key":"2151_CR36","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1155\/2008\/509459","volume":"22","author":"I Zandieh","year":"2008","unstructured":"Zandieh I, Krygier D, Wong V, et al. The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can J Gastroenterol. 2008;22:388\u2013392.","journal-title":"Can J Gastroenterol"},{"key":"2151_CR37","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2010.06.046","volume":"139","author":"MP Manns","year":"2010","unstructured":"Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010;139:1198\u20131206.","journal-title":"Gastroenterology"},{"key":"2151_CR38","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1345\/aph.1Q244","volume":"45","author":"KR Snider","year":"2011","unstructured":"Snider KR, Potter TG. Budesonide for the treatment of autoimmune hepatitis. Ann Pharmacother. 2011;45:1144\u20131150.","journal-title":"Ann Pharmacother"},{"key":"2151_CR39","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0168-8278(00)80271-8","volume":"33","author":"PD Richardson","year":"2000","unstructured":"Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol. 2000;33:371\u2013375.","journal-title":"J Hepatol"},{"key":"2151_CR40","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1155\/2004\/504591","volume":"18","author":"SM Devlin","year":"2004","unstructured":"Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol. 2004;18:321\u2013326.","journal-title":"Can J Gastroenterol"},{"key":"2151_CR41","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/01.mcg.0000177260.72692.e8","volume":"39","author":"AJ Czaja","year":"2005","unstructured":"Czaja AJ, Carpenter HA. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J Clin Gastroenterol. 2005;39:819\u2013825.","journal-title":"J Clin Gastroenterol"},{"key":"2151_CR42","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.cgh.2007.02.030","volume":"5","author":"I Inductivo-Yu","year":"2007","unstructured":"Inductivo-Yu I, Adams A, Gish RG, et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol. 2007;5:799\u2013802.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2151_CR43","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1111\/j.1572-0241.2008.02180.x","volume":"103","author":"EM Hennes","year":"2008","unstructured":"Hennes EM, Oo YH, Schramm C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol. 2008;103:3063\u20133070.","journal-title":"Am J Gastroenterol"},{"key":"2151_CR44","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cgh.2008.04.006","volume":"6","author":"JT Hlivko","year":"2008","unstructured":"Hlivko JT, Shiffman ML, Stravitz RT, et al. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008;6:1036\u20131040.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2151_CR45","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jhep.2009.02.024","volume":"51","author":"MM Aw","year":"2009","unstructured":"Aw MM, Dhawan A, Samyn M, Bargiota A, Mieli-Vergani G. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol. 2009;51:156\u2013160.","journal-title":"J Hepatol"},{"key":"2151_CR46","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1007\/s10620-008-0632-0","volume":"54","author":"DC Wolf","year":"2009","unstructured":"Wolf DC, Bojito L, Facciuto M, Lebovics E. Mycophenolate mofetil for autoimmune hepatitis: a single practice experience. Dig Dis Sci. 2009;54:2519\u20132522.","journal-title":"Dig Dis Sci"},{"key":"2151_CR47","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1155\/2010\/891252","volume":"24","author":"K Sharzehi","year":"2010","unstructured":"Sharzehi K, Huang MA, Schreibman IR, Brown KA. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can J Gastroenterol. 2010;24:588\u2013592.","journal-title":"Can J Gastroenterol"},{"key":"2151_CR48","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jhep.2010.12.032","volume":"55","author":"K Zachou","year":"2011","unstructured":"Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients. J Hepatol. 2011;55:636\u2013646.","journal-title":"J Hepatol"},{"key":"2151_CR49","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2036.2011.04727.x","volume":"34","author":"AM Baven-Pronk","year":"2011","unstructured":"Baven-Pronk AM, Coenraad MJ, van Buuren HR, et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther. 2011;34:335\u2013343.","journal-title":"Aliment Pharmacol Ther"},{"key":"2151_CR50","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1586\/egh.11.45","volume":"5","author":"HI Fallatah","year":"2011","unstructured":"Fallatah HI, Akbar HO. Mycophenolate mofetil as a rescue therapy for autoimmune hepatitis patients who are not responsive to standard therapy. Expert Rev Gastroenterol Hepatol. 2011;5:517\u2013522.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2151_CR51","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0016-5085(87)90862-6","volume":"92","author":"AJ Czaja","year":"1987","unstructured":"Czaja AJ, Beaver SJ, Shiels MT. Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology. 1987;92:215\u2013219.","journal-title":"Gastroenterology"},{"key":"2151_CR52","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/j.1572-0241.2007.01153.x","volume":"102","author":"AJ Montano-Loza","year":"2007","unstructured":"Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol. 2007;102:1005\u20131012.","journal-title":"Am J Gastroenterol"},{"key":"2151_CR53","unstructured":"Kanzler S, Lohr H, Gerken G, Galle PR, Lohse AW. Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience. Z Gastroenterol. 2001;39:339\u2013341, 344\u2013338."},{"key":"2151_CR54","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0168-8278(00)00095-7","volume":"34","author":"S Kanzler","year":"2001","unstructured":"Kanzler S, Gerken G, Lohr H, et al. Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol. 2001;34:354\u2013355.","journal-title":"J Hepatol"},{"key":"2151_CR55","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0016-5085(81)90126-8","volume":"80","author":"AJ Czaja","year":"1981","unstructured":"Czaja AJ, Wolf AM, Baggenstoss AH. Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology. 1981;80:687\u2013692.","journal-title":"Gastroenterology"},{"key":"2151_CR56","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/MCG.0b013e318154af74","volume":"42","author":"S Luth","year":"2008","unstructured":"Luth S, Herkel J, Kanzler S, et al. Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J Clin Gastroenterol. 2008;42:926\u2013930.","journal-title":"J Clin Gastroenterol"},{"key":"2151_CR57","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM198101013040102","volume":"304","author":"AJ Czaja","year":"1981","unstructured":"Czaja AJ, Ludwig J, Baggenstoss AH, Wolf A. Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis. N Engl J Med. 1981;304:5\u20139.","journal-title":"N Engl J Med"},{"key":"2151_CR58","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s10620-010-1243-0","volume":"55","author":"AJ Czaja","year":"2010","unstructured":"Czaja AJ. Late relapse of type 1 autoimmune hepatitis after corticosteroid withdrawal. Dig Dis Sci. 2010;55:1761\u20131769.","journal-title":"Dig Dis Sci"},{"key":"2151_CR59","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1111\/j.1572-0241.2004.30457.x","volume":"99","author":"S Verma","year":"2004","unstructured":"Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol. 2004;99:1510\u20131516.","journal-title":"Am J Gastroenterol."},{"key":"2151_CR60","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/0016-5085(84)90186-0","volume":"87","author":"GL Davis","year":"1984","unstructured":"Davis GL, Czaja AJ, Ludwig J. Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology. 1984;87:1222\u20131227.","journal-title":"Gastroenterology"},{"key":"2151_CR61","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/BF01076196","volume":"22","author":"SW Schalm","year":"1977","unstructured":"Schalm SW, Korman MG, Summerskill WH, Czaja AJ, Baggenstoss AH. Severe chronic active liver disease. Prognostic significance of initial morphologic patterns. Am J Dig Dis. 1977;22:973\u2013980.","journal-title":"Am J Dig Dis"},{"key":"2151_CR62","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0046-8177(72)80072-8","volume":"3","author":"AH Baggenstoss","year":"1972","unstructured":"Baggenstoss AH, Soloway RD, Summerskill WH, Elveback LR, Schoenfield LJ. Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution. Hum Pathol. 1972;3:183\u2013198.","journal-title":"Hum Pathol"},{"key":"2151_CR63","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1034\/j.1600-0676.2003.00810.x","volume":"23","author":"AJ Czaja","year":"2003","unstructured":"Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int. 2003;23:116\u2013123.","journal-title":"Liver Int"},{"key":"2151_CR64","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1007\/BF02235164","volume":"16","author":"RD Soloway","year":"1971","unstructured":"Soloway RD, Baggenstoss AH, Schoenfield LJ, Summerskill WH. Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy. Am J Dig Dis. 1971;16:1082\u20131086.","journal-title":"Am J Dig Dis"},{"key":"2151_CR65","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/0016-5085(80)90135-3","volume":"79","author":"A Theodossi","year":"1980","unstructured":"Theodossi A, Skene AM, Portmann B, et al. Observer variation in assessment of liver biopsies including analysis by kappa statistics. Gastroenterology. 1980;79:232\u2013241.","journal-title":"Gastroenterology"},{"key":"2151_CR66","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1053\/jhep.2002.34944","volume":"36","author":"AJ Czaja","year":"2002","unstructured":"Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology. 2002;36:479\u2013497.","journal-title":"Hepatology"},{"key":"2151_CR67","doi-asserted-by":"crossref","unstructured":"Muratori L, Muratori P, Lanzoni G, Ferri S, Lenzi M. Application of the 2010 American Association for the study of liver diseases criteria of remission to a cohort of Italian patients with autoimmune hepatitis. Hepatology. 2010;52:1857; author reply 1857\u20131858.","DOI":"10.1002\/hep.23924"},{"key":"2151_CR68","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jhep.2005.06.006","volume":"43","author":"Y Miyake","year":"2005","unstructured":"Miyake Y, Iwasaki Y, Terada R, et al. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol. 2005;43:951\u2013957.","journal-title":"J Hepatol"},{"key":"2151_CR69","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1089-3261(02)00018-1","volume":"6","author":"D Vergani","year":"2002","unstructured":"Vergani D, Choudhuri K, Bogdanos DP, Mieli-Vergani G. Pathogenesis of autoimmune hepatitis. Clin Liver Dis. 2002;6:727\u2013737.","journal-title":"Clin Liver Dis"},{"key":"2151_CR70","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1586\/17474124.1.1.113","volume":"1","author":"AJ Czaja","year":"2007","unstructured":"Czaja AJ. Autoimmune hepatitis. Part A: Pathogenesis. Expert Rev Gastroenterol Hepatol. 2007;1:113\u2013128.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2151_CR71","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1478-3231.2007.01444.x","volume":"27","author":"AJ Montano-Loza","year":"2007","unstructured":"Montano-Loza AJ, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int. 2007;27:507\u2013515.","journal-title":"Liver Int"},{"key":"2151_CR72","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/hep.1840080414","volume":"8","author":"AJ Stellon","year":"1988","unstructured":"Stellon AJ, Keating JJ, Johnson PJ, McFarlane IG, Williams R. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology. 1988;8:781\u2013784.","journal-title":"Hepatology"},{"key":"2151_CR73","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJM199510123331502","volume":"333","author":"PJ Johnson","year":"1995","unstructured":"Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med. 1995;333:958\u2013963.","journal-title":"N Engl J Med"},{"key":"2151_CR74","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/hep.1840110621","volume":"11","author":"AJ Czaja","year":"1990","unstructured":"Czaja AJ. Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology. 1990;11:1044\u20131049.","journal-title":"Hepatology"},{"key":"2151_CR75","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1478-3231.2005.01141.x","volume":"25","author":"S Seela","year":"2005","unstructured":"Seela S, Sheela H, Boyer JL. Autoimmune hepatitis type 1: safety and efficacy of prolonged medical therapy. Liver Int. 2005;25:734\u2013739.","journal-title":"Liver Int"},{"key":"2151_CR76","first-page":"221","volume":"8","author":"SW Schalm","year":"1976","unstructured":"Schalm SW, Ammon HV, Summerskill WH. Failure of customary treatment in chronic active liver disease: causes and management. Ann Clin Res. 1976;8:221\u2013227.","journal-title":"Ann Clin Res"},{"key":"2151_CR77","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/0016-5085(83)90030-6","volume":"85","author":"AJ Czaja","year":"1983","unstructured":"Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology. 1983;85:713\u2013717.","journal-title":"Gastroenterology"},{"key":"2151_CR78","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/hep.24141","volume":"53","author":"AD Yeoman","year":"2011","unstructured":"Yeoman AD, Westbrook RH, Zen Y, et al. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology. 2011;53:926\u2013934.","journal-title":"Hepatology"},{"key":"2151_CR79","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/hep.1840150208","volume":"15","author":"L Sanchez-Urdazpal","year":"1992","unstructured":"Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RA, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology. 1992;15:215\u2013221.","journal-title":"Hepatology"},{"key":"2151_CR80","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/0016-5085(88)90503-3","volume":"95","author":"AJ Czaja","year":"1988","unstructured":"Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology. 1988;95:448\u2013453.","journal-title":"Gastroenterology"},{"key":"2151_CR81","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1007\/s10620-010-1268-4","volume":"55","author":"AJ Czaja","year":"2010","unstructured":"Czaja AJ. Autoantibodies as prognostic markers in autoimmune liver disease. Dig Dis Sci. 2010;55:2144\u20132161.","journal-title":"Dig Dis Sci"},{"key":"2151_CR82","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jhep.2009.02.026","volume":"51","author":"AJ Czaja","year":"2009","unstructured":"Czaja AJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol. 2009;51:161\u2013167.","journal-title":"J Hepatol"},{"key":"2151_CR83","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/0016-5085(93)90157-8","volume":"105","author":"AJ Czaja","year":"1993","unstructured":"Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology. 1993;105:1502\u20131507.","journal-title":"Gastroenterology"},{"key":"2151_CR84","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/hep.510250211","volume":"25","author":"AJ Czaja","year":"1997","unstructured":"Czaja AJ, Strettell MD, Thomson LJ, et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology. 1997;25:317\u2013323.","journal-title":"Hepatology"},{"key":"2151_CR85","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.21074","volume":"43","author":"AJ Czaja","year":"2006","unstructured":"Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology. 2006;43:532\u2013538.","journal-title":"Hepatology"},{"key":"2151_CR86","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/0090-1229(88)90022-0","volume":"48","author":"P Paoli De","year":"1988","unstructured":"De Paoli P, Battistin S, Santini GF. Age-related changes in human lymphocyte subsets: progressive reduction of the CD4 CD45R (suppressor inducer) population. Clin Immunol Immunopathol. 1988;48:290\u2013296.","journal-title":"Clin Immunol Immunopathol"},{"key":"2151_CR87","first-page":"71","volume":"10","author":"DM Murasko","year":"1990","unstructured":"Murasko DM, Goonewardene IM. T-cell function in aging: mechanisms of decline. Annu Rev Gerontol Geriatr. 1990;10:71\u201396.","journal-title":"Annu Rev Gerontol Geriatr"},{"key":"2151_CR88","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3109\/08916939108997112","volume":"8","author":"E Talor","year":"1991","unstructured":"Talor E, Rose NR. Hypothesis: the aging paradox and autoimmune disease. Autoimmunity. 1991;8:245\u2013249.","journal-title":"Autoimmunity"},{"key":"2151_CR89","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1002\/eji.1830221134","volume":"22","author":"R Schwab","year":"1992","unstructured":"Schwab R, Russo C, Weksler ME. Altered major histocompatibility complex-restricted antigen recognition by T cells from elderly humans. Eur J Immunol. 1992;22:2989\u20132993.","journal-title":"Eur J Immunol"},{"key":"2151_CR90","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0140-6736(68)92893-6","volume":"2","author":"MJ Rowley","year":"1968","unstructured":"Rowley MJ, Buchanan H, Mackay IR. Reciprocal change with age in antibody to extrinsic and intrinsic antigens. Lancet. 1968;2:24\u201326.","journal-title":"Lancet"},{"key":"2151_CR91","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cgh.2007.12.048","volume":"6","author":"AJ Czaja","year":"2008","unstructured":"Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008;6:379\u2013388.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2151_CR92","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0140-6736(87)92024-1","volume":"1","author":"M Manns","year":"1987","unstructured":"Manns M, Gerken G, Kyriatsoulis A, Staritz M. Meyer zum Buschenfelde KH. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet. 1987;1:292\u2013294.","journal-title":"Lancet"},{"key":"2151_CR93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.1840180102","volume":"18","author":"E Stechemesser","year":"1993","unstructured":"Stechemesser E, Klein R, Berg PA. Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis. Hepatology. 1993;18:1\u20139.","journal-title":"Hepatology"},{"key":"2151_CR94","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/S0140-6736(00)02166-8","volume":"355","author":"I Wies","year":"2000","unstructured":"Wies I, Brunner S, Henninger J, et al. Identification of target antigen for SLA\/LP autoantibodies in autoimmune hepatitis. Lancet. 2000;355:1510\u20131515.","journal-title":"Lancet"},{"key":"2151_CR95","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaut.2009.07.005","volume":"34","author":"M Volkmann","year":"2010","unstructured":"Volkmann M, Luithle D, Zentgraf H, et al. SLA\/LP\/tRNP((Ser)Sec) antigen in autoimmune hepatitis: identification of the native protein in human hepatic cell extract. J Autoimmun. 2010;34:59\u201365.","journal-title":"J Autoimmun"},{"key":"2151_CR96","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1053\/jhep.2001.22218","volume":"33","author":"M Volkmann","year":"2001","unstructured":"Volkmann M, Martin L, Baurle A, et al. Soluble liver antigen: isolation of a 35-kd recombinant protein (SLA-p35) specifically recognizing sera from patients with autoimmune hepatitis. Hepatology. 2001;33:591\u2013596.","journal-title":"Hepatology"},{"key":"2151_CR97","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1046\/j.1365-2249.2000.01280.x","volume":"121","author":"M Costa","year":"2000","unstructured":"Costa M, Rodriguez-Sanchez JL, Czaja AJ, Gelpi C. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients withtype-1 autoimmune hepatitis. Clin Exp Immunol. 2000;121:364\u2013374.","journal-title":"Clin Exp Immunol"},{"key":"2151_CR98","doi-asserted-by":"crossref","first-page":"9739","DOI":"10.1073\/pnas.89.20.9739","volume":"89","author":"C Gelpi","year":"1992","unstructured":"Gelpi C, Sontheimer EJ, Rodriguez-Sanchez JL. Autoantibodies against a serine tRNA-protein complex implicated in cotranslational selenocysteine insertion. Proc Natl Acad Sci USA. 1992;89:9739\u20139743.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2151_CR99","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/gut.51.2.259","volume":"51","author":"M Baeres","year":"2002","unstructured":"Baeres M, Herkel J, Czaja AJ, et al. Establishment of standardised SLA\/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut. 2002;51:259\u2013264.","journal-title":"Gut"},{"key":"2151_CR100","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/0891693021000054101","volume":"35","author":"AJ Czaja","year":"2002","unstructured":"Czaja AJ, Shums Z, Norman GL. Frequency and significance of antibodies to soluble liver antigen\/liver pancreas in variant autoimmune hepatitis. Autoimmunity. 2002;35:475\u2013483.","journal-title":"Autoimmunity"},{"key":"2151_CR101","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1053\/jhep.2002.32092","volume":"35","author":"Y Ma","year":"2002","unstructured":"Ma Y, Okamoto M, Thomas MG, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology. 2002;35:658\u2013664.","journal-title":"Hepatology"},{"key":"2151_CR102","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1572-0241.2002.05479.x","volume":"97","author":"AJ Czaja","year":"2002","unstructured":"Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen\/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol. 2002;97:413\u2013419.","journal-title":"Am J Gastroenterol"},{"key":"2151_CR103","doi-asserted-by":"crossref","first-page":"S250","DOI":"10.1016\/S0168-8278(07)62258-2","volume":"46","author":"C Liaskos","year":"2007","unstructured":"Liaskos C, Bogdanos DP, Rigopoulou EI, et al. Antibody responses specific for soluble liver antigen co-occur with Ro-52 autoantibodies in patients with autoimmune hepatitis (abstract). J Hepatol. 2007;46:S250.","journal-title":"J Hepatol"},{"key":"2151_CR104","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/j.1478-3231.2009.01986.x","volume":"29","author":"V Eyraud","year":"2009","unstructured":"Eyraud V, Chazouilleres O, Ballot E, et al. Significance of antibodies to soluble liver antigen\/liver pancreas: a large French study. Liver Int. 2009;29:857\u2013864.","journal-title":"Liver Int"},{"key":"2151_CR105","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1478-3231.2011.02502.x","volume":"32","author":"AJ Montano-Loza","year":"2012","unstructured":"Montano-Loza AJ, Shums Z, Norman GL, Czaja AJ. Prognostic implications of antibodies to Ro\/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver Int. 2012;32:85\u201392.","journal-title":"Liver Int"},{"key":"2151_CR106","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1053\/j.gastro.2008.07.029","volume":"135","author":"H Mix","year":"2008","unstructured":"Mix H, Weiler-Normann C, Thimme R, et al. Identification of CD4 T-cell epitopes in soluble liver antigen\/liver pancreas autoantigen in autoimmune hepatitis. Gastroenterology. 2008;135:2107\u20132118.","journal-title":"Gastroenterology"},{"key":"2151_CR107","first-page":"313","volume":"51","author":"AJ Czaja","year":"2005","unstructured":"Czaja AJ. Diverse manifestations and evolving treatments of autoimmune hepatitis. Minerva Gastroenterol Dietol. 2005;51:313\u2013333.","journal-title":"Minerva Gastroenterol Dietol"},{"key":"2151_CR108","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1055\/s-0029-1233530","volume":"29","author":"AJ Czaja","year":"2009","unstructured":"Czaja AJ. Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients. Semin Liver Dis. 2009;29:315\u2013330.","journal-title":"Semin Liver Dis"},{"key":"2151_CR109","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.3748\/wjg.15.2314","volume":"15","author":"AJ Czaja","year":"2009","unstructured":"Czaja AJ, Bayraktar Y. Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment. World J Gastroenterol. 2009;15:2314\u20132328.","journal-title":"World J Gastroenterol"},{"key":"2151_CR110","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.bpg.2011.09.011","volume":"25","author":"AJ Czaja","year":"2011","unstructured":"Czaja AJ. Autoimmune hepatitis in special patient populations. Best Pract Res Clin Gastroenterol. 2011;25:689\u2013700.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2151_CR111","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1111\/j.1572-0241.2001.05272.x","volume":"96","author":"KN Lim","year":"2001","unstructured":"Lim KN, Casanova RL, Boyer TD, Bruno CJ. Autoimmune hepatitis in African Americans: presenting features and response to therapy. Am J Gastroenterol. 2001;96:3390\u20133394.","journal-title":"Am J Gastroenterol"},{"key":"2151_CR112","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/hep.21884","volume":"46","author":"S Verma","year":"2007","unstructured":"Verma S, Torbenson M, Thuluvath PJ. The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology. 2007;46:1828\u20131835.","journal-title":"Hepatology"},{"key":"2151_CR113","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1111\/j.1572-0241.2002.06019.x","volume":"97","author":"KJ Hurlburt","year":"2002","unstructured":"Hurlburt KJ, McMahon BJ, Deubner H, et al. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol. 2002;97:2402\u20132407.","journal-title":"Am J Gastroenterol"},{"key":"2151_CR114","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1155\/2008\/642432","volume":"22","author":"GY Minuk","year":"2008","unstructured":"Minuk GY, Liu S, Kaita K, et al. Autoimmune hepatitis in a North American Aboriginal\/First Nations population. Can J Gastroenterol. 2008;22:829\u2013834.","journal-title":"Can J Gastroenterol"},{"key":"2151_CR115","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/gut.50.5.713","volume":"50","author":"T Zolfino","year":"2002","unstructured":"Zolfino T, Heneghan MA, Norris S, et al. Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut. 2002;50:713\u2013717.","journal-title":"Gut"},{"key":"2151_CR116","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1440-1746.1998.tb00674.x","volume":"13","author":"K Nakamura","year":"1998","unstructured":"Nakamura K, Yoneda M, Yokohama S, et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol. 1998;13:490\u2013495.","journal-title":"J Gastroenterol Hepatol"},{"key":"2151_CR117","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0896-8411(03)00084-2","volume":"21","author":"H Miyakawa","year":"2003","unstructured":"Miyakawa H, Kawashima Y, Kitazawa E, et al. Low frequency of anti-SLA\/LP autoantibody in Japanese adult patients with autoimmune liver diseases: analysis with recombinant antigen assay. J Autoimmun. 2003;21:77\u201382.","journal-title":"J Autoimmun"},{"key":"2151_CR118","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1111\/j.1572-0241.1999.01229.x","volume":"94","author":"PL Bittencourt","year":"1999","unstructured":"Bittencourt PL, Goldberg AC, Cancado EL, et al. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am J Gastroenterol. 1999;94:1906\u20131913.","journal-title":"Am J Gastroenterol"},{"key":"2151_CR119","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0168-8278(02)00182-4","volume":"37","author":"AJ Czaja","year":"2002","unstructured":"Czaja AJ, Souto EO, Bittencourt PL, et al. Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J Hepatol. 2002;37:302\u2013308.","journal-title":"J Hepatol"},{"key":"2151_CR120","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0198-8859(94)90008-6","volume":"41","author":"L Fainboim","year":"1994","unstructured":"Fainboim L, Marcos Y, Pando M, et al. Chronic active autoimmune hepatitis in children. Strong association with a particular HLA-DR6 (DRB1*1301) haplotype. Hum Immunol. 1994;41:146\u2013150.","journal-title":"Hum Immunol"},{"key":"2151_CR121","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/hep.510300611","volume":"30","author":"M Pando","year":"1999","unstructured":"Pando M, Larriba J, Fernandez GC, et al. Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology. 1999;30:1374\u20131380.","journal-title":"Hepatology"},{"key":"2151_CR122","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1478-3231.2005.01088.x","volume":"25","author":"R D\u2019Souza","year":"2005","unstructured":"D\u2019Souza R, Sinnott P, Glynn MJ, Sabin CA, Foster GR. An unusual form of autoimmune hepatitis in young Somalian men. Liver Int. 2005;25:325\u2013330.","journal-title":"Liver Int"},{"key":"2151_CR123","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/hep.21580","volume":"45","author":"GC Nguyen","year":"2007","unstructured":"Nguyen GC, Segev DL, Thuluvath PJ. Racial disparities in the management of hospitalized patients with cirrhosis and complications of portal hypertension: a national study. Hepatology. 2007;45:1282\u20131289.","journal-title":"Hepatology"},{"key":"2151_CR124","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/hep.22223","volume":"47","author":"GC Nguyen","year":"2008","unstructured":"Nguyen GC, Thuluvath PJ. Racial disparity in liver disease: biological, cultural, or socioeconomic factors. Hepatology. 2008;47:1058\u20131066.","journal-title":"Hepatology"},{"key":"2151_CR125","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1111\/j.1572-0241.2008.02022.x","volume":"103","author":"YN Flores","year":"2008","unstructured":"Flores YN, Yee HF Jr, Leng M, et al. Risk factors for chronic liver disease in Blacks, Mexican Americans, and Whites in the United States: results from NHANES IV, 1999\u20132004. Am J Gastroenterol. 2008;103:2231\u20132238.","journal-title":"Am J Gastroenterol"},{"key":"2151_CR126","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/0140-6736(91)92858-Y","volume":"337","author":"S Vento","year":"1991","unstructured":"Vento S, Garofano T, Di Perri G, et al. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet. 1991;337:1183\u20131187.","journal-title":"Lancet"},{"key":"2151_CR127","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0168-8278(95)80336-X","volume":"23","author":"HI Huppertz","year":"1995","unstructured":"Huppertz HI, Treichel U, Gassel AM, Jeschke R. Meyer zum Buschenfelde KH. Autoimmune hepatitis following hepatitis A virus infection. J Hepatol. 1995;23:204\u2013208.","journal-title":"J Hepatol"},{"key":"2151_CR128","doi-asserted-by":"crossref","unstructured":"Fainboim L, Canero Velasco MC, Marcos CY, et al. Protracted, but not acute, hepatitis A virus infection is strongly associated with HLA-DRB*1301, a marker for pediatric autoimmune hepatitis. Hepatology. 2001;33:1512\u20131517.","DOI":"10.1053\/jhep.2001.24562"},{"key":"2151_CR129","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.3748\/wjg.v11.i12.1862","volume":"11","author":"P Muratori","year":"2005","unstructured":"Muratori P, Czaja AJ, Muratori L, et al. Genetic distinctions between autoimmune hepatitis in Italy and North America. World J Gastroenterol. 2005;11:1862\u20131866.","journal-title":"World J Gastroenterol"},{"key":"2151_CR130","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10620-006-9495-4","volume":"52","author":"P Muratori","year":"2007","unstructured":"Muratori P, Czaja AJ, Muratori L, et al. Evidence of a genetic basis for the different geographic occurrences of liver\/kidney microsomal antibody type 1 in hepatitis C. Dig Dis Sci. 2007;52:179\u2013184.","journal-title":"Dig Dis Sci"},{"key":"2151_CR131","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1053\/j.gastro.2011.04.026","volume":"140","author":"MP Manns","year":"2011","unstructured":"Manns MP. Autoimmune hepatitis: the dilemma of rare diseases. Gastroenterology. 2011;140:1874\u20131876.","journal-title":"Gastroenterology"},{"key":"2151_CR132","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1159\/000329805","volume":"29","author":"MP Manns","year":"2011","unstructured":"Manns MP, Strassburg CP. Therapeutic strategies for autoimmune hepatitis. Dig Dis. 2011;29:411\u2013415.","journal-title":"Dig Dis"},{"key":"2151_CR133","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ceca.2009.07.006","volume":"46","author":"JD Turner","year":"2009","unstructured":"Turner JD, Thomas AP, Reeves JP, Hantash BM. Calcineurin activation by slow calcium release from intracellular stores suppresses protein kinase C regulation of L-type calcium channels in L6 cells. Cell Calcium. 2009;46:242\u2013247.","journal-title":"Cell Calcium"},{"key":"2151_CR134","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2174\/0929867043455576","volume":"11","author":"S Martinez\u2013Martinez","year":"2004","unstructured":"Martinez\u2013Martinez S, Redondo JM. Inhibitors of the calcineurin\/NFAT pathway. Curr Med Chem. 2004;11:997\u20131007.","journal-title":"Curr Med Chem"},{"key":"2151_CR135","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.biocel.2003.07.002","volume":"36","author":"E Serfling","year":"2004","unstructured":"Serfling E, Berberich-Siebelt F, Avots A, et al. NFAT and NF-kappaB factors-the distant relatives. Int J Biochem Cell Biol. 2004;36:1166\u20131170.","journal-title":"Int J Biochem Cell Biol"},{"key":"2151_CR136","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nri1632","volume":"5","author":"F Macian","year":"2005","unstructured":"Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol. 2005;5:472\u2013484.","journal-title":"Nat Rev Immunol"},{"key":"2151_CR137","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/FTD.0b013e3181aa36cd","volume":"31","author":"H Jonge de","year":"2009","unstructured":"de Jonge H, Naesens M, Kuypers DR. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther Drug Monit. 2009;31:416\u2013435.","journal-title":"Ther Drug Monit"},{"key":"2151_CR138","first-page":"515","volume":"2","author":"DM Canafax","year":"1983","unstructured":"Canafax DM, Ascher NL. Cyclosporine immunosuppression. Clin Pharm. 1983;2:515\u2013524.","journal-title":"Clin Pharm"},{"key":"2151_CR139","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0162-3109(00)00186-7","volume":"47","author":"AC Allison","year":"2000","unstructured":"Allison AC. Immunosuppressive drugs: the first 50\u00a0years and a glance forward. Immunopharmacology. 2000;47:63\u201383.","journal-title":"Immunopharmacology"},{"key":"2151_CR140","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3727\/000000001783986387","volume":"10","author":"WY Almawi","year":"2001","unstructured":"Almawi WY, Assi JW, Chudzik DM, Jaoude MM, Rieder MJ. Inhibition of cytokine production and cytokine-stimulated T-cell activation by FK506 (tacrolimus)1. Cell Transplant. 2001;10:615\u2013623.","journal-title":"Cell Transplant"},{"key":"2151_CR141","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2133\/dmpk.22.328","volume":"22","author":"K Iwasaki","year":"2007","unstructured":"Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet. 2007;22:328\u2013335.","journal-title":"Drug Metab Pharmacokinet"},{"key":"2151_CR142","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/0092-8674(91)90124-H","volume":"66","author":"J Liu","year":"1991","unstructured":"Liu J, Farmer JD Jr, Lane WS, et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991;66:807\u2013815.","journal-title":"Cell"},{"key":"2151_CR143","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1007\/s00018-010-0437-0","volume":"67","author":"A Galat","year":"2010","unstructured":"Galat A, Bua J. Molecular aspects of cyclophilins mediating therapeutic actions of their ligands. Cell Mol Life Sci. 2010;67:3467\u20133488.","journal-title":"Cell Mol Life Sci"},{"key":"2151_CR144","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/341755a0","volume":"341","author":"JJ Siekierka","year":"1989","unstructured":"Siekierka JJ, Hung SH, Poe M, Lin CS, Sigal NH. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature. 1989;341:755\u2013757.","journal-title":"Nature"},{"key":"2151_CR145","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1126\/science.7518616","volume":"265","author":"T Wang","year":"1994","unstructured":"Wang T, Donahoe PK, Zervos AS. Specific interaction of type I receptors of the TGF-beta family with the immunophilin FKBP-12. Science. 1994;265:674\u2013676.","journal-title":"Science"},{"key":"2151_CR146","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1046\/j.1365-3083.2003.01221.x","volume":"57","author":"KA Jorgensen","year":"2003","unstructured":"Jorgensen KA, Koefoed-Nielsen PB, Karamperis N. Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporin A and tacrolimus. Scand J Immunol. 2003;57:93\u201398.","journal-title":"Scand J Immunol"},{"key":"2151_CR147","doi-asserted-by":"crossref","unstructured":"Pissaia A, Jr, Aoudjehane L, Ben Othman S, et al. Cyclosporine inhibits profibrotic effects of interleukin-4 and transforming growth factor beta on human intrahepatic fibroblasts cultured in vitro. Transplant Proc. 2010;42:4343\u20134346.","DOI":"10.1016\/j.transproceed.2010.09.124"},{"key":"2151_CR148","doi-asserted-by":"crossref","first-page":"463","DOI":"10.5694\/j.1326-5377.1985.tb123140.x","volume":"143","author":"SP Mistilis","year":"1985","unstructured":"Mistilis SP, Vickers CR, Darroch MH, McCarthy SW. Cyclosporin, a new treatment for autoimmune chronic active hepatitis. Med J Aust. 1985;143:463\u2013465.","journal-title":"Med J Aust"},{"key":"2151_CR149","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S0168-8278(05)80615-4","volume":"21","author":"KE Sherman","year":"1994","unstructured":"Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol. 1994;21:1040\u20131047.","journal-title":"J Hepatol"},{"key":"2151_CR150","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0168-8278(99)80065-8","volume":"30","author":"F Alvarez","year":"1999","unstructured":"Alvarez F, Ciocca M, Canero-Velasco C, et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol. 1999;30:222\u2013227.","journal-title":"J Hepatol"},{"key":"2151_CR151","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/01.mpg.0000235975.75120.38","volume":"43","author":"M Cuarterolo","year":"2006","unstructured":"Cuarterolo M, Ciocca M, Velasco CC, et al. Follow-up of children with autoimmune hepatitis treated with cyclosporine. J Pediatr Gastroenterol Nutr. 2006;43:635\u2013639.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2151_CR152","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.cgh.2010.10.013","volume":"9","author":"ML Cuarterolo","year":"2011","unstructured":"Cuarterolo ML, Ciocca ME, Lopez SI, de Davila MT, Alvarez F. Immunosuppressive therapy allows recovery from liver failure in children with autoimmune hepatitis. Clin Gastroenterol Hepatol. 2011;9:145\u2013149.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2151_CR153","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1478-3231.2005.01107.x","volume":"25","author":"N Chatur","year":"2005","unstructured":"Chatur N, Ramji A, Bain VG, et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int. 2005;25:723\u2013727.","journal-title":"Liver Int"},{"key":"2151_CR154","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2165\/00002018-199512050-00006","volume":"12","author":"M Winkler","year":"1995","unstructured":"Winkler M, Christians U. A risk-benefit assessment of tacrolimus in transplantation. Drug Saf. 1995;12:348\u2013357.","journal-title":"Drug Saf"},{"key":"2151_CR155","doi-asserted-by":"crossref","first-page":"S462","DOI":"10.1111\/j.1872-034X.2007.00287.x","volume":"37","author":"AW Lohse","year":"2007","unstructured":"Lohse AW, Weiler-Norman C, Burdelski M. De novo autoimmune hepatitis after liver transplantation. Hepatol Res. 2007;37:S462.","journal-title":"Hepatol Res"},{"key":"2151_CR156","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","volume":"47","author":"AC Allison","year":"2000","unstructured":"Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85\u2013118.","journal-title":"Immunopharmacology"},{"key":"2151_CR157","doi-asserted-by":"crossref","first-page":"s2","DOI":"10.1177\/096120330501400102","volume":"14","author":"AC Allison","year":"2005","unstructured":"Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus. 2005;14:s2\u2013s8.","journal-title":"Lupus"},{"key":"2151_CR158","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1399-0012.2006.00597.x","volume":"20","author":"C Morath","year":"2006","unstructured":"Morath C, Schwenger V, Beimler J, et al. Antifibrotic actions of mycophenolic acid. Clin Transpl. 2006;20:25\u201329.","journal-title":"Clin Transpl"},{"key":"2151_CR159","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jhep.2009.03.011","volume":"51","author":"AJ Czaja","year":"2009","unstructured":"Czaja AJ. Mycophenolate mofetil to the rescue in autoimmune hepatitis: a fresh sprout on the decision tree. J Hepatol. 2009;51:8\u201310.","journal-title":"J Hepatol"},{"key":"2151_CR160","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/ajh.21753","volume":"85","author":"B Adams","year":"2010","unstructured":"Adams B, Lazarchick J, Medina AM, et al. Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis. Am J Hematol. 2010;85:627\u2013629.","journal-title":"Am J Hematol"},{"key":"2151_CR161","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajmg.a.32117","volume":"146A","author":"A Perez-Aytes","year":"2008","unstructured":"Perez-Aytes A, Ledo A, Boso V, et al. In utero exposure to mycophenolate mofetil: a characteristic phenotype? Am J Med Genet A. 2008;146A:1\u20137.","journal-title":"Am J Med Genet A"},{"key":"2151_CR162","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/ajmg.a.32685","volume":"149A","author":"MT Anderka","year":"2009","unstructured":"Anderka MT, Lin AE, Abuelo DN, Mitchell AA, Rasmussen SA. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genet A. 2009;149A:1241\u20131248.","journal-title":"Am J Med Genet A"},{"key":"2151_CR163","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S1701-2163(16)34622-9","volume":"32","author":"C Klieger-Grossmann","year":"2010","unstructured":"Klieger-Grossmann C, Chitayat D, Lavign S, et al. Prenatal exposure to mycophenolate mofetil: an updated estimate. J Obstet Gynaecol Can. 2010;32:794\u2013797.","journal-title":"J Obstet Gynaecol Can"},{"key":"2151_CR164","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/ajmg.a.33934","volume":"155A","author":"AE Lin","year":"2011","unstructured":"Lin AE, Singh KE, Strauss A, et al. An additional patient with mycophenolate mofetil embryopathy: cardiac and facial analyses. Am J Med Genet A. 2011;155A:748\u2013756.","journal-title":"Am J Med Genet A"},{"key":"2151_CR165","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1034\/j.1399-3046.1999.00015.x","volume":"3","author":"MG Seikaly","year":"1999","unstructured":"Seikaly MG. Mycophenolate mofetil\u2014is it worth the cost? The in-favor opinion. Pediatr Transplant. 1999;3:79\u201382.","journal-title":"Pediatr Transplant"},{"key":"2151_CR166","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1517\/14656566.7.2.145","volume":"7","author":"MA Heneghan","year":"2006","unstructured":"Heneghan MA, Al-Chalabi T, McFarlane IG. Cost-effectiveness of pharmacotherapy for autoimmune hepatitis. Expert Opin Pharmacother. 2006;7:145\u2013156.","journal-title":"Expert Opin Pharmacother"},{"key":"2151_CR167","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2165\/00003495-198428060-00001","volume":"28","author":"SP Clissold","year":"1984","unstructured":"Clissold SP, Heel RC. Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs. 1984;28:485\u2013518.","journal-title":"Drugs"},{"key":"2151_CR168","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1053\/gast.2000.0010000001","volume":"119","author":"AJ Czaja","year":"2000","unstructured":"Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology. 2000;119:1312\u20131316.","journal-title":"Gastroenterology"},{"key":"2151_CR169","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.3748\/wjg.v9.i12.2681","volume":"9","author":"A Geier","year":"2003","unstructured":"Geier A, Gartung C, Dietrich CG, et al. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J Gastroenterol. 2003;9:2681\u20132685.","journal-title":"World J Gastroenterol"},{"key":"2151_CR170","unstructured":"Efe C, Ozaslan E, Kav T, et al. Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome. Autoimmun Rev. Epub. 10\/06\/2011."},{"key":"2151_CR171","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jhep.2010.09.017","volume":"54","author":"AW Lohse","year":"2011","unstructured":"Lohse AW, Gil H. Reactivation of autoimmune hepatitis during budesonide monotherapy, and response to standard treatment. J Hepatol. 2011;54:837\u2013839.","journal-title":"J Hepatol"},{"key":"2151_CR172","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1478-3231.2008.01904.x","volume":"29","author":"AJ Czaja","year":"2009","unstructured":"Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int. 2009;29:816\u2013823.","journal-title":"Liver Int"},{"key":"2151_CR173","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hep.20732","volume":"42","author":"JJ Feld","year":"2005","unstructured":"Feld JJ, Dinh H, Arenovich T, et al. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology. 2005;42:53\u201362.","journal-title":"Hepatology"},{"key":"2151_CR174","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3748\/wjg.v16.i8.934","volume":"16","author":"AJ Czaja","year":"2010","unstructured":"Czaja AJ. Difficult treatment decisions in autoimmune hepatitis. World J Gastroenterol. 2010;16:934\u2013947.","journal-title":"World J Gastroenterol"},{"key":"2151_CR175","doi-asserted-by":"crossref","unstructured":"de Boer NK, van Nieuwkerk CM, Aparicio Pages MN, et al. Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine. Eur J Gastroenterol Hepatol. 2005;17:457\u2013461.","DOI":"10.1097\/00042737-200504000-00012"},{"key":"2151_CR176","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/01.tp.0000194860.21533.b9","volume":"81","author":"N Nikolaeva","year":"2006","unstructured":"Nikolaeva N, Bemelman FJ, Yong SL, van Lier RA, ten Berge IJ. Rapamycin does not induce anergy but inhibits expansion and differentiation of alloreactive human T cells. Transplantation. 2006;81:445\u2013454.","journal-title":"Transplantation"},{"key":"2151_CR177","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.freeradbiomed.2005.04.011","volume":"39","author":"MJ Ronis","year":"2005","unstructured":"Ronis MJ, Butura A, Sampey BP, et al. Effects of N-acetylcysteine on ethanol-induced hepatotoxicity in rats fed via total enteral nutrition. Free Radic Biol Med. 2005;39:619\u2013630.","journal-title":"Free Radic Biol Med"},{"key":"2151_CR178","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11011-010-9201-2","volume":"25","author":"C Bemeur","year":"2010","unstructured":"Bemeur C, Vaquero J, Desjardins P, Butterworth RF. N-acetylcysteine attenuates cerebral complications of non-acetaminophen-induced acute liver failure in mice: antioxidant and anti-inflammatory mechanisms. Metab Brain Dis. 2010;25:241\u2013249.","journal-title":"Metab Brain Dis"},{"key":"2151_CR179","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/jn\/138.10.1872","volume":"138","author":"JN Baumgardner","year":"2008","unstructured":"Baumgardner JN, Shankar K, Hennings L, et al. N-acetylcysteine attenuates progression of liver pathology in a rat model of nonalcoholic steatohepatitis. J Nutr. 2008;138:1872\u20131879.","journal-title":"J Nutr"},{"key":"2151_CR180","doi-asserted-by":"crossref","unstructured":"Setshedi M, Longato L, Petersen DR, et al. Limited therapeutic effect of N-acetylcysteine on hepatic insulin resistance in an experimental model of alcohol-induced steatohepatitis. Alcohol Clin Exp Res. Epub. 07\/28\/2011.","DOI":"10.1111\/j.1530-0277.2011.01569.x"},{"key":"2151_CR181","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.cbi.2010.09.021","volume":"188","author":"D Desai","year":"2010","unstructured":"Desai D, Kaushal N, Gandhi UH, et al. Synthesis and evaluation of the anti-inflammatory properties of selenium-derivatives of celecoxib. Chem Biol Interact. 2010;188:446\u2013456.","journal-title":"Chem Biol Interact"},{"key":"2151_CR182","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/337181a0","volume":"337","author":"CA Smith","year":"1989","unstructured":"Smith CA, Williams GT, Kingston R, Jenkinson EJ, Owen JJ. Antibodies to CD3\/T-cell receptor complex induce death by apoptosis in immature T cells in thymic cultures. Nature. 1989;337:181\u2013184.","journal-title":"Nature"},{"key":"2151_CR183","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4049\/jimmunol.168.2.933","volume":"168","author":"MG Herrath von","year":"2002","unstructured":"von Herrath MG, Coon B, Wolfe T, Chatenoud L. Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance. J Immunol. 2002;168:933\u2013941.","journal-title":"J Immunol"},{"key":"2151_CR184","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.coph.2004.03.012","volume":"4","author":"L Chatenoud","year":"2004","unstructured":"Chatenoud L. Anti-CD3 antibodies: towards clinical antigen-specific immunomodulation. Curr Opin Pharmacol. 2004;4:403\u2013407.","journal-title":"Curr Opin Pharmacol"},{"key":"2151_CR185","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1073\/pnas.91.1.123","volume":"91","author":"L Chatenoud","year":"1994","unstructured":"Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA. 1994;91:123\u2013127.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2151_CR186","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1056\/NEJMoa012864","volume":"346","author":"KC Herold","year":"2002","unstructured":"Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002;346:1692\u20131698.","journal-title":"N Engl J Med"},{"key":"2151_CR187","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2337\/diabetes.54.6.1763","volume":"54","author":"KC Herold","year":"2005","unstructured":"Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala\u2013Ala) results in improvement in C-peptide responses and clinical parameters for at least 2\u00a0years after onset of type 1 diabetes. Diabetes. 2005;54:1763\u20131769.","journal-title":"Diabetes"},{"key":"2151_CR188","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/35069112","volume":"410","author":"JC Schwartz","year":"2001","unstructured":"Schwartz JC, Zhang X, Fedorov AA, Nathenson SG, Almo SC. Structural basis for co-stimulation by the human CTLA-4\/B7-2 complex. Nature. 2001;410:604\u2013608.","journal-title":"Nature"},{"key":"2151_CR189","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1600-065X.2008.00639.x","volume":"223","author":"KJ Scalapino","year":"2008","unstructured":"Scalapino KJ, Daikh DI. CTLA-4: a key regulatory point in the control of autoimmune disease. Immunol Rev. 2008;223:143\u2013155.","journal-title":"Immunol Rev"},{"key":"2151_CR190","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/ncprheum0142","volume":"2","author":"CM Weyand","year":"2006","unstructured":"Weyand CM, Goronzy JJ. T-cell-targeted therapies in rheumatoid arthritis. Nat Clin Pract Rheumatol. 2006;2:201\u2013210.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"2151_CR191","doi-asserted-by":"crossref","unstructured":"Maxwell L, Singh JA. Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev. 2009:CD007277.","DOI":"10.1002\/14651858.CD007277.pub2"},{"key":"2151_CR192","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.2174\/092986707781696591","volume":"14","author":"W Chen","year":"2007","unstructured":"Chen W, Perruche S, Li J. CD4+ CD25+ T regulatory cells and TGF-beta in mucosal immune system: the good and the bad. Curr Med Chem. 2007;14:2245\u20132249.","journal-title":"Curr Med Chem"},{"key":"2151_CR193","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2004.03.008","volume":"41","author":"MS Longhi","year":"2004","unstructured":"Longhi MS, Ma Y, Bogdanos DP, et al. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol. 2004;41:31\u201337.","journal-title":"J Hepatol"},{"key":"2151_CR194","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.4049\/jimmunol.176.7.4484","volume":"176","author":"MS Longhi","year":"2006","unstructured":"Longhi MS, Hussain MJ, Mitry RR, et al. Functional study of CD4+ CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol. 2006;176:4484\u20134491.","journal-title":"J Immunol"},{"key":"2151_CR195","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/hep.22071","volume":"47","author":"MS Longhi","year":"2008","unstructured":"Longhi MS, Meda F, Wang P, et al. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology. 2008;47:581\u2013591.","journal-title":"Hepatology"},{"key":"2151_CR196","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/clin.1997.4412","volume":"84","author":"DL Jacobson","year":"1997","unstructured":"Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 1997;84:223\u2013243.","journal-title":"Clin Immunol Immunopathol"},{"key":"2151_CR197","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/jhep.2002.34734","volume":"36","author":"WR Kim","year":"2002","unstructured":"Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology. 2002;36:227\u2013242.","journal-title":"Hepatology"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-012-2151-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-012-2151-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-012-2151-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T19:39:11Z","timestamp":1641929951000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-012-2151-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,3]]},"references-count":197,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["2151"],"URL":"https:\/\/doi.org\/10.1007\/s10620-012-2151-2","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,3]]}}}